<DOC>
	<DOCNO>NCT01933724</DOCNO>
	<brief_summary>This randomize controlled trial patient diagnosis granulomatosis polyangiitis ( GPA ; Wegener 's ) remission evaluate effect use low-dose glucocorticoid ( 5 mg/day prednisone ) compare stop glucocorticoid treatment entirely ( 0 mg/day prednisone ) rate disease relapse/disease flare . This study novel approach conduct randomized clinical trial community set . This study conduct parallel similar study establish vasculitis institution . This study patient centric approach research subject recruit online social medium vasculitis support network . Participants consent online receive care regular treat physician travel additional doctor visit require . Study participant consent study complete online questionnaires prednisone dose feeling .</brief_summary>
	<brief_title>The Assessment Prednisone In Remission Trial ( TAPIR ) - Patient Centric Approach</brief_title>
	<detailed_description>This open label pilot study randomize 60 participant GPA remission affect sinonasal tract , oral mucosa , skin , musculoskeletal system , pulmonary parenchyma , disease feature warrant administration 20 mg/day within last 12 month . At time enrollment , participant need take prednisone dose ≥ 5mg/day ≤ 20 mg/day . All enrol participant instructed reduce daily dose prednisone accord treat physician . Once participant reach prednisone dose 5mg/day , randomize 1:1 ratio continue prednisone 5 mg/day taper prednisone 0 mg/day . Participants follow approximately six month reach prednisone dose 5 mg/day . The primary study outcome proportion participant increase prednisone disease relapse within 6 month randomization . Participant data collect via study combine complementary study conduct Vasculitis Clinical Research Consortium ( VCRC ) clinical center .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Antineoplastic Agents , Hormonal</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Hormones , Hormone Substitutes , Hormone Antagonists</mesh_term>
	<criteria>1 . Established diagnosis granulomatosis polyangiitis ( GPA ) ( verified medical record review Protocol Oversight Management Team ) patient need meet least 2 5 classification GPA , least one must criterion e. The modified American College Rheumatology ( ACR ) criterion : 1 . Nasal oral inflammation , define development painful painless oral ulcer purulent bloody nasal discharge 2 . Abnormal chest radiograph , define presence nodule , fix infiltrates , cavity . 3 . Active urinary sediment , define microscopic hematuria ( &gt; 5 red blood cell per high power field ) red blood cell cast 4 . Granulomatosis inflammation biopsy , define histologic change show granulomatous inflammation within wall artery perivascular extravascular area . Note : Pauciimmune glomerulonephritis see kidney biopsy suffice criterion . 5 . Positive antineutrophil cytoplasmic antibody ( ANCA ) test specific proteinase3 measure enzymelinked immunoassay 2 . Patients myeloperoxidase ( MPO ) positive ANCA negative still eligible study meet criterion felt GPA . 3 . Active disease within prior 12 month ( initial presentation relapse ) time active disease require treatment prednisone ≥ 20 mg/day ( verified medical record review Protocol Oversight Management Team ) 4 . Disease remission time enrollment ( verified medical record review Protocol Oversight Management Team ) 5 . Prednisone dose time enrollment ≥ 5mg/day ≤ 20 mg/day 6 . Participant age 18 year great 7 . If patient take immunosuppressive medication agent prednisone ( maintenance agent ) maintenance agent must stable dose one month prior enrollment plan treat physician change dose ( safety purposes/toxicity ) duration study ( month 6 visit early termination ) . Acceptable maintenance agent include azathioprine , leflunomide , 6mercaptopurine , methotrexate , mycophenolate mofetil , mycophenolate sodium . Patients may trimethoprim/sulfamethoxazole ( TMP/SMX ) use either maintenance agent prophylaxis infection . TMP/SMX may use combination drug . 7.1 Rituximab acceptable maintenance agent last dose give least one month prior enrollment additional dos plan ) duration study ( month 6 visit early termination ) . If patient receive rituximab prescribe another maintenance agent , patient eligible plan treat physician change dose maintenance ( safety purposes/toxicity ) duration study ( month 6 visit early termination ) . 7.2 If patient regularly take trimethoprim/sulfamethoxazole dose patient eligible plan treat physician change dose enrollment ( dose reduction discontinuation safety purposes/toxicity ) duration study . 8 . Agreement Treating Physician 0mg/day prednisone 5mg/day prednisone standard care 9 . Participant 's Treating Physician locate United States 1 . Comorbid condition moderate likelihood require course prednisone within one year enrollment ( e.g . chronic obstructive pulmonary disease ( COPD ) , asthma , adrenal insufficiency ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>granulomatosis polyangiitis</keyword>
	<keyword>GPA</keyword>
	<keyword>Wegeners '</keyword>
	<keyword>WG</keyword>
	<keyword>vasculitis</keyword>
	<keyword>taper</keyword>
	<keyword>prednisone</keyword>
	<keyword>glucocorticoid</keyword>
	<keyword>ANCA-associated vasculitis</keyword>
	<keyword>AAV</keyword>
	<keyword>Wegener Granulomatosis</keyword>
	<keyword>Systemic Vasculitis</keyword>
	<keyword>Lung disease , interstitial</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones , Hormone Substitutes , Hormone Antagonists</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antineoplastic Agents , Hormonal</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
</DOC>